



DURECT Corporation Presenting at the CIBC Biotechnology & Specialty Pharmaceuticals Conference

CUPERTINO, Calif., April 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Biotechnology & Specialty Pharmaceuticals Conference being held at the Millenium Broadway Hotel in New York City. Matthew J. Hogan, Chief Financial Officer, will be presenting at the conference on April 11 at 12:45 p.m. Eastern Time.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>)

A live audio webcast of the presentation will be available by accessing DURECT's homepage at <http://www.durect.com> and clicking "Investor Relations."

DURECT Corporation is an emerging specialty pharmaceutical company developing pharmaceutical systems based on its proprietary drug delivery platform technologies. The Company currently has a number of late-stage pharmaceutical products in development addressing large markets in pain management, with a number of research programs underway targeting chronic disease and other therapeutic areas. For more information, please visit <http://www.durect.com>.

SOURCE DURECT Corporation

Matthew J. Hogan, Chief Financial Officer of DURECT Corporation, +1-408-777-4936; or Jeremiah Hall, Senior Vice President of Feinstein Kean Healthcare, +1-415-677-2700, jeremiah.hall@fkhealth.com, for DURECT Corporation

<http://www.durect.com/>